No association between phosphatase and tensin homolog genetic polymorphisms and colon cancer

Table 1 Descriptive characteristics of the CWRU/kentucky colon cancer genetic epidemiology study population

	Cases (n = 421 )	Controls (n = 483)	P1
Age2 (yr)	62.7 ± 10.6	57.6 ± 11.2	< 0.0001
Gender (%)
Female	214 (50.8)	307 (63.6)	0.0001
Male	207 (49.2)	176 (36.4)
Race (%)
Caucasian	394 (93.6)	450 (93.2)	0.3
African-American	22 (5.2)	21 (4.4)
Other	5 (1.2)	12 (2.5)
BMI34 (kg/m2)	29.2 ± 6.2	28.2 ± 6.0	< 0.0001
Family History35
Yes	94 (26.8)	72 (17.1)	0.0015
No	257 (73.2)	349 (82.9)
NSAID use36 (%)
Yes	235 (64.2)	306 (68.9)	0.18
No	131 (35.8)	138 (31.1)
Physical activity3 (%)
Vigorous	165 (42.7)	247 (53.8)	0.006
Moderate	106 (27.5)	98 (21.4)
Light	115 (29.8)	114 (24.8)

¹P-value of significance difference between cases and controls in a χ² test (discrete variables and genotypes) or t-test (continuous);

²Age (mean ± SD) at diagnosis for cases and age at recruitment for controls;

³Calculations based on cases and controls with available information;

⁴BMI (mean ± SD);

⁵Family history of first-degree relatives with colorectal cancer;

⁶NSAID: Yes = either ibuprofen or aspirin use in the last 6 mo.

Table 2 Associations of PTEN SNPs with colon cancer n (%)

SNP	Cases	Controls	Base model1			Full model2
			OR	95% CI	P	OR	95% CI	P
rs926091
CC	289 (69.1)	351 (72.8)	1.0			1.0
CT	122 (29.2)	122 (25.3)	1.18	0.87-1.60	0.61	1.12	0.79-1.60	0.73
TT	7 (1.7)	9 (1.9)	1.12	0.40-3.13	0.71	0.99	0.29-3.41	0.92
rs2299939
CC	270 (64.6)	325 (67.4)	1.0			1.0
CA	134 (32.1)	147 (30.5)	1.15	0.85-1.55	0.56	1.01	0.72-1.42	0.18
AA	14 (3.3)	10 (2.1)	1.96	0.82-4.66	0.25	2.13	0.84-5.38	0.11
rs2248293
TT	181 (43.3)	212 (44.0)	1.0			1.0
TC	196 (46.9)	210 (43.6)	1.04	0.78-1.39	0.21	1.04	0.47-1.45	0.52
CC	41 (9.8)	60 (12.4)	0.77	0.48-1.22	0.23	0.86	0.51-1.46	0.51
rs12357281
GG	353 (84.4)	408 (84.7)	1.0			1.0
GC/CC3	65 (15.6)	74 (15.3)	0.93	0.64-1.37	0.98	0.99	0.65-1.53	0.98

¹Base model adjusted for age, gender and race;

²Full model further adjusted for BMI, family history of colorectal cancer, NSAID use, and physical activity based on 328 cases and 390 controls;

³Only three cases and two controls were of genotype CC, so they were combined with the heterozygotes to ensure validity of model fit.

Table 3 PTEN haplotype associations with colon cancer n (%)

Haplotype3	Frequency	Cases	Controls	Base model1			Full model2
				OR	95% CI	P	OR	95% CI	P
A-G-T-C	0.180	146 (48.2)	157 (51.8)	1.16	0.865-1.550	0.32	1.05	0.751-1.456	0.79
C-C-T-C	0.079	53 (48.2)	57 (51.8)	0.98	0.643-1.485	0.91	1.04	0.642-1.669	0.89
C-G-C-C	0.184	88 (42.1)	121 (57.9)	0.76	0.548-1.060	0.11	0.94	0.645-1.356	0.72
C-G-C-T	0.151	71 (52.6)	64 (47.4)	1.44	0.979-0.106	0.06	1.31	0.849-2.029	0.22
C-G-T-C	0.398	58 (41.1)	83 (58.9)	0.75	0.510-1.089	0.13	0.70	0.449-1.082	0.11

¹Base model adjusted for age, gender and race;

²Full model further adjusted for BMI, family history of colorectal cancer, NSAID use, and physical activity based on 329 cases and 390 controls;

³Five other haplotypes representing a total of six participants were removed due to rarity.